Ganitumab (AMG 479) Inhibits IGF-II-Dependent Ovarian Cancer Growth and Potentiates Platinum-Based ChemotherapyBELTRAN, Pedro J; CALZONE, Frank J; GUORONG YANG et al.Clinical cancer research (Print). 2014, Vol 20, Num 11, pp 2947-2958, issn 1078-0432, 12 p.Article

A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancerCOHN, A. L; TABERNERO, J; SUZUKI, S et al.Annals of oncology. 2013, Vol 24, Num 7, pp 1777-1785, issn 0923-7534, 9 p.Article

Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal CancerVAN CUTSEM, Eric; ENG, Cathy; HONGJIE DENG et al.Clinical cancer research (Print). 2014, Vol 20, Num 16, pp 4240-4250, issn 1078-0432, 11 p.Article

Putative Predictive Biomarkers of Survival in Patients with Metastatic Pancreatic Adenocarcinoma Treated with Gemcitabine and Ganitumab, an IGF1R InhibitorMCCAFFERY, Ian; TUDOR, Yanyan; LI CHEN et al.Clinical cancer research (Print). 2013, Vol 19, Num 15, pp 4282-4289, issn 1078-0432, 8 p.Article

Phase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R), in Japanese patients with advanced solid tumorsMURAKAMI, Haruyasu; DOI, Toshihiko; TAKUBO, Takatoshi et al.Cancer chemotherapy and pharmacology. 2012, Vol 70, Num 3, pp 407-414, issn 0344-5704, 8 p.Article

A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancerKINDLER, H. L; RICHARDS, D. A; MCGREIVY, J et al.Annals of oncology. 2012, Vol 23, Num 11, pp 2834-2842, issn 0923-7534, 9 p.Article